|Chemical and physical data|
|Molar mass||408.534 g/mol|
|3D model (Jmol)||Interactive image|
|(what is this?)|
Omapatrilat (INN) is a novel antihypertensive agent that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme. NEP inhibition results in elevated natriuretic peptide levels, promoting natriuresis, diuresis, vasodilation, and reductions in preload and ventricular remodeling.
Omapatrilat angioedema was attributed to its dual mechanism of action, inhibiting both angiotensin converting enzyme (ACE), and neutral endopeptidase, both of these enzymes are responsible for the metabolism of bradykinin which causes vasodilation, angioedema, and airway obstruction.
The drug was promoted for possible uses in congestive heart failure.